Five Prime Therapeutics Inc. (NASDAQ:FPRX) Director Peder Jensen sold 12,195 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $49.50, for a total transaction of $603,652.50. Following the sale, the director now owns 12,195 shares in the company, valued at $603,652.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
A number of equities research analysts have recently weighed in on FPRX shares. Credit Suisse Group AG restated a “buy” rating on shares of Five Prime Therapeutics in a report on Tuesday, July 12th. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Tuesday, April 5th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $48.00 price objective on shares of Five Prime Therapeutics in a report on Thursday, May 19th. Leerink Swann restated a “buy” rating and issued a $45.00 price objective on shares of Five Prime Therapeutics in a report on Friday, July 15th. Finally, BMO Capital Markets started coverage on shares of Five Prime Therapeutics in a report on Tuesday, April 12th. They issued a “market perform” rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $45.67.
A hedge fund recently bought a new stake in Five Prime Therapeutics stock. Russell Frank Co acquired a new stake in Five Prime Therapeutics Inc. (NASDAQ:FPRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 30,412 shares of the company’s stock, valued at approximately $1,265,000. Russell Frank Co owned approximately 0.11% of Five Prime Therapeutics at the end of the most recent quarter.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.22. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. The business had revenue of $6.50 million for the quarter, compared to analysts’ expectations of $5.26 million. Five Prime Therapeutics’s quarterly revenue was up 51.2% compared to the same quarter last year. On average, equities research analysts predict that Five Prime Therapeutics Inc. will post ($2.35) earnings per share for the current fiscal year.
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.
